EMG
CLLS

Ellington Management Group’s Cellectis CLLS Stock Holding History

Ellington Management Group’s Portfolio CLLS Stock Details CLLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-12,400
Closed -$210K – 709
2016
Q4 		$210K Buy
+12,400
New +$229K 0.03% 426

Other funds holding CLLS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Ellington Management Group's CLLS Position: Q1 2017 in Review

Ellington Management Group sold out of Cellectis (CLLS) in Q1 2017, closing a stake of 12,400 shares — an estimated $210K sold.

Ellington Management Group first reported a position in CLLS in Q4 2016 and held it in 1 quarter. The position peaked at $210K in Q4 2016. 40 funds tracked by Wall St. Rank hold CLLS as of Q1 2017.

  • Ellington Management Group reported no remaining Cellectis position as of Q1 2017 after selling out during the quarter.
  • Ellington Management Group sold 12,400 Cellectis shares in Q1 2017, an estimated $210K.
  • Ellington Management Group first reported a position in Cellectis in Q4 2016 and held it in 1 quarter.
  • Ellington Management Group's Cellectis position peaked at $210K in Q4 2016.
  • 40 funds tracked by Wall St. Rank held Cellectis as of Q1 2017.

Based on Ellington Management Group's 13F filing for Q1 2017, filed 15 May 2017.